
The antidiabetic drug acarbose suppresses age-related lesions in C57BL/6 mice in an organ dependent manner
Author(s) -
Sneh Lata Gupta,
Zhou Jiang,
Warren Ladiges
Publication year - 2021
Publication title -
aging pathobiology and therapeutics
Language(s) - English
Resource type - Journals
ISSN - 2690-1803
DOI - 10.31491/apt.2021.06.060
Subject(s) - acarbose , drug , medicine , kidney , endocrinology , renal pathology , diabetes mellitus , physiology , pharmacology
Acarbose (Acb) is an antidiabetic drug used to reduce blood glucose by inhibiting the conversion of complex carbohydrates into simple sugars. It has also shown promise as an anti-aging drug by increasing lifespan in mice but studies have not been reported on the effects of short-term treatment in aging mice. To address this question, 20-month-old C57BL/6 male and female mice were given a standard diet, or a diet supplemented with 1000 ppm Acb for 3 months. After this period, mice were assessed for age-related lesions as readouts for the delay in the progression of aging. Results showed there was a significant decrease in lesions of the heart and kidney in mice treated with Acb suggesting that Acb can suppress cardiac and renal pathology associated with increasing age.